These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31446998)

  • 1. Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
    Ryan SL; Beard S; Barr MP; Umezawa K; Heavey S; Godwin P; Gray SG; Cormican D; Finn SP; Gately KA; Davies AM; Thompson EW; Richard DJ; O'Byrne KJ; Adams MN; Baird AM
    Lung Cancer; 2019 Sep; 135():217-227. PubMed ID: 31446998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer.
    Xiao L; Lan X; Shi X; Zhao K; Wang D; Wang X; Li F; Huang H; Liu J
    Cell Death Dis; 2017 May; 8(5):e2803. PubMed ID: 28518145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
    Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
    Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.
    Heavey S; Godwin P; Baird AM; Barr MP; Umezawa K; Cuffe S; Finn SP; O'Byrne KJ; Gately K
    Cancer Biol Ther; 2014 Oct; 15(10):1367-77. PubMed ID: 25025901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
    Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
    Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of NF-κB/miR-21/PTEN pathway sensitizes non-small cell lung cancer to cisplatin.
    Yang Z; Fang S; Di Y; Ying W; Tan Y; Gu W
    PLoS One; 2015; 10(3):e0121547. PubMed ID: 25799148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
    Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
    Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
    Wang LH; Li Y; Yang SN; Wang FY; Hou Y; Cui W; Chen K; Cao Q; Wang S; Zhang TY; Wang ZZ; Xiao W; Yang JY; Wu CF
    Br J Cancer; 2014 Jan; 110(2):341-52. PubMed ID: 24300974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.
    Barr MP; Gray SG; Hoffmann AC; Hilger RA; Thomale J; O'Flaherty JD; Fennell DA; Richard D; O'Leary JJ; O'Byrne KJ
    PLoS One; 2013; 8(1):e54193. PubMed ID: 23349823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-small-cell lung cancer cells.
    Milone MR; Lombardi R; Roca MS; Bruzzese F; Addi L; Pucci B; Budillon A
    J Cell Physiol; 2019 Jun; 234(6):9077-9092. PubMed ID: 30362533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNPY2 enhances resistance to apoptosis induced by cisplatin via activation of NF-κB pathway in human non-small cell lung cancer.
    Yu D; Qin Y; Jun-Qiang L; Shun-Lin G
    Biomed Pharmacother; 2018 Jul; 103():1658-1663. PubMed ID: 29864955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.
    Wang B; Jing T; Jin W; Chen J; Wu C; Wang M; Liu Y
    J Exp Clin Cancer Res; 2020 Aug; 39(1):170. PubMed ID: 32854746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS; Zheng YL; Zhao J; Chun X
    Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
    Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
    Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lumbrokinase Extracted from
    Hua C; Guo Z; Dai M; Zhou J; Ge H; Xue G; Xu F; Ru L; Lv K; Zhang G; Zheng L; Wang M; Teng Y; Yu W; Guo W
    Biomolecules; 2024 Jun; 14(7):. PubMed ID: 39062456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling.
    Su J; Wu S; Tang W; Qian H; Zhou H; Guo T
    Mol Carcinog; 2016 Nov; 55(11):1822-1832. PubMed ID: 26513225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
    Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
    Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
    Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
    Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.